| A Study of Two Different Formulations of LY3209590 in Healthy Participants (NCT04768842) | Eli Lilly and Company | 2021-03-03 |
| A Study of LY3410738 in Healthy Adult Participants (NCT06181045) | Eli Lilly and Company | 2021-02-24 |
| A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer (NCT04557384) | Eli Lilly and Company | 2021-02-23 |
| A Study of Abemaciclib in Indian Women With Advanced Breast Cancer (NCT04707196) | Eli Lilly and Company | 2021-02-22 |
| A Study of LY3549492 in Healthy Participants (NCT04758234) | Eli Lilly and Company | 2021-02-22 |
| A Study of Lasmiditan in Healthy Volunteers (NCT04749914) | Eli Lilly and Company | 2021-02-15 |
| Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants (NCT06190678) | Eli Lilly and Company | 2021-02-01 |
| A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) (NCT04701658) | Eli Lilly and Company | 2021-02-01 |
| A Study of Continuous Heart Rate Monitoring in Healthy Participants (NCT04682184) | Eli Lilly and Company | 2021-01-27 |
| A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes (NCT04667182) | Eli Lilly and Company | 2021-01-25 |
| Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (NCT04408924) | Eli Lilly and Company | 2021-01-20 |
| A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants (NCT06215430) | Eli Lilly and Company | 2021-01-11 |
| A Study of LY3462817 in Participants With Rheumatoid Arthritis (NCT04634253) | Eli Lilly and Company | 2021-01-04 |
| A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants (NCT06180980) | Eli Lilly and Company | 2021-01-04 |
| A Safety Study of LY3526318 in Healthy Participants (NCT04682119) | Eli Lilly and Company | 2020-12-29 |
| Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants (NCT06190691) | Eli Lilly and Company | 2020-12-18 |
| A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants (NCT06215521) | Eli Lilly and Company | 2020-12-15 |
| A Study of LY3537031 in Healthy Participants (NCT04648865) | Eli Lilly and Company | 2020-12-09 |
| A Study of LY3041658 in Healthy Participants (NCT04653168) | Eli Lilly and Company | 2020-12-07 |
| A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes (NCT04591626) | Eli Lilly and Company | 2020-12-07 |
| A Study of LY3561774 in Participants With Dyslipidemia (NCT04644809) | Eli Lilly and Company | 2020-11-30 |
| A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (NCT04616326) | Eli Lilly and Company | 2020-11-25 |
| A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes (NCT04641312) | Eli Lilly and Company | 2020-11-25 |
| A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus (NCT04586907) | Eli Lilly and Company | 2020-11-23 |
| A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) (NCT04640077) | Eli Lilly and Company | 2020-11-23 |
| Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (NCT04603001) | Eli Lilly and Company | 2020-11-19 |
| A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) (NCT04626297) | Eli Lilly and Company | 2020-11-17 |
| A Study of LY3451838 in Participants With Migraine (NCT04498910) | Eli Lilly and Company | 2020-11-16 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis (NCT04627038) | Eli Lilly and Company | 2020-11-12 |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma (NCT04238819) | Eli Lilly and Company | 2020-11-09 |
| A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) (NCT04605991) | Eli Lilly and Company | 2020-11-04 |
| A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 (NCT04611789) | Eli Lilly and Company | 2020-11-02 |
| A Study of Mirikizumab in Healthy Participants (NCT04607733) | Eli Lilly and Company | 2020-11-02 |
| A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes (NCT04585776) | Eli Lilly and Company | 2020-10-30 |
| A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS (NCT04517253) | Eli Lilly and Company | 2020-10-27 |
| A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus (NCT04235959) | Eli Lilly and Company | 2020-10-21 |
| A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants (NCT04586920) | Eli Lilly and Company | 2020-10-20 |
| A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (NCT04537923) | Eli Lilly and Company | 2020-10-19 |
| A Study of LY3522348 in Healthy Participants (NCT04559568) | Eli Lilly and Company | 2020-10-15 |
| A Study of LY3502970 in Participants With Type 2 Diabetes (NCT04426474) | Eli Lilly and Company | 2020-10-08 |
| A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist (NCT04294147) | Eli Lilly and Company | 2020-10-06 |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations (NCT04521686) | Eli Lilly and Company | 2020-10-01 |
| Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A (NCT04541628) | Eli Lilly and Company | 2020-09-28 |
| A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants (NCT06180954) | Eli Lilly and Company | 2020-09-23 |
| A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide (NCT04407234) | Eli Lilly and Company | 2020-09-15 |
| A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants (NCT04548219) | Eli Lilly and Company | 2020-09-11 |
| A Safety Study of LY3493269 in Healthy Participants (NCT04498390) | Eli Lilly and Company | 2020-09-03 |
| A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants (NCT06180967) | Eli Lilly and Company | 2020-09-03 |
| A Study of LY3819253 (LY-CoV555) in Healthy Participants (NCT04537910) | Eli Lilly and Company | 2020-09-02 |
| A Study of LY3041658 in Adults With Hidradenitis Suppurativa (NCT04493502) | Eli Lilly and Company | 2020-08-26 |
| A Study of LY3493269 in Participants With Type 2 Diabetes (NCT04515576) | Eli Lilly and Company | 2020-08-25 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain (NCT04529096) | Eli Lilly and Company | 2020-08-25 |
| A Study of Tirzepatide in Overweight and Very Overweight Participants (NCT04311411) | Eli Lilly and Company | 2020-08-24 |
| A Study of LY3473329 in Healthy Participants (NCT04472676) | Eli Lilly and Company | 2020-08-18 |
| A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants (NCT06181006) | Eli Lilly and Company | 2020-08-14 |
| A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants (NCT04392271) | Eli Lilly and Company | 2020-08-06 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (NCT04497987) | Eli Lilly and Company | 2020-08-02 |
| A Study of Ramucirumab (LY3009806) in Healthy Participants (NCT04495478) | Eli Lilly and Company | 2020-07-30 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain (NCT04476108) | Eli Lilly and Company | 2020-07-15 |
| A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes (NCT04484779) | Eli Lilly and Company | 2020-07-14 |
| A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants (NCT04451408) | Eli Lilly and Company | 2020-07-07 |
| A Study of LY3209590 in Participants With Type 1 Diabetes (NCT04450407) | Eli Lilly and Company | 2020-07-06 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis (NCT04456686) | Eli Lilly and Company | 2020-07-01 |
| A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus (NCT04450394) | Eli Lilly and Company | 2020-07-01 |
| A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (NCT04396574) | Eli Lilly and Company | 2020-06-30 |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (NCT04232553) | Eli Lilly and Company | 2020-06-22 |
| A Study of LY3832479 (LY-CoV016) in Healthy Participants (NCT04441931) | Eli Lilly and Company | 2020-06-19 |
| A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) (NCT04437511) | Eli Lilly and Company | 2020-06-19 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (NCT04427501) | Eli Lilly and Company | 2020-06-17 |
| A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (NCT04396236) | Eli Lilly and Company | 2020-06-15 |
| Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (NCT04392154) | Eli Lilly and Company | 2020-06-15 |
| A Study of LY3461767 in Healthy Participants (NCT04352114) | Eli Lilly and Company | 2020-06-15 |
| A Study of Baricitinib (LY3009104) in Participants With COVID-19 (NCT04421027) | Eli Lilly and Company | 2020-06-12 |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (NCT04106219) | Eli Lilly and Company | 2020-06-11 |
| A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (NCT04255433) | Eli Lilly and Company | 2020-05-29 |
| A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 (NCT04411628) | Eli Lilly and Company | 2020-05-28 |
| A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) (NCT04004611) | Eli Lilly and Company | 2020-05-18 |
| A Study of LY3127804 in Participants With COVID-19 (NCT04342897) | Eli Lilly and Company | 2020-04-20 |
| A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis (NCT04285229) | Eli Lilly and Company | 2020-04-10 |
| A Study of LY3478045 in Healthy Participants (NCT04270370) | Eli Lilly and Company | 2020-03-16 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (NCT04280081) | Eli Lilly and Company | 2020-03-16 |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma (NCT04145700) | Eli Lilly and Company | 2020-03-04 |
| A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus (NCT04276428) | Eli Lilly and Company | 2020-02-28 |
| A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants (NCT04172987) | Eli Lilly and Company | 2020-02-26 |
| A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps (NCT04276207) | Eli Lilly and Company | 2020-02-25 |
| A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (NCT04050553) | Eli Lilly and Company | 2020-02-24 |
| A Study of LY3478006 in Healthy Participants (NCT04230122) | Eli Lilly and Company | 2020-02-17 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NCT04194944) | Eli Lilly and Company | 2020-02-17 |
| A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) (NCT04088396) | Eli Lilly and Company | 2020-02-12 |
| Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (NCT04250350) | Eli Lilly and Company | 2020-02-11 |
| A Study of Two Formulations of Ixekizumab in Healthy Participants (NCT04259346) | Eli Lilly and Company | 2020-02-05 |
| Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (NCT04250337) | Eli Lilly and Company | 2020-02-03 |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain (NCT05986292) | Eli Lilly and Company | 2020-01-30 |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (NCT04145349) | Eli Lilly and Company | 2020-01-22 |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (NCT05999994) | Eli Lilly and Company | 2020-01-22 |
| A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (NCT04148937) | Eli Lilly and Company | 2020-01-16 |
| A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants (NCT04178733) | Eli Lilly and Company | 2020-01-10 |
| A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus (NCT04161976) | Eli Lilly and Company | 2019-12-27 |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer (NCT04071262) | Eli Lilly and Company | 2019-12-20 |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) (NCT04143802) | Eli Lilly and Company | 2019-12-18 |